ScripsAmerica, Inc. specializes in crafting and selling non-sterile creams for topical and transdermal pain management. Beyond its product offerings, the company provides medication dispensing support to individual doctors and supplies administrative and billing solutions for independent pharmacies. It also functions as a distributor, supplying pharmaceutical goods to standalone drugstores and other healthcare providers. Established in 2008, ScripsAmerica is based in Clifton, New Jersey. The company initially filed for Chapter 11 bankruptcy protection on September 7, 2016, before its reorganization case was subsequently changed to Chapter 7 liquidation on February 8, 2017.
—
ScripsAmerica, Inc. specializes in crafting and selling non-sterile creams for topical and transdermal pain management. Beyond its product offerings, the company provides medication dispensing support to individual doctors and supplies administrative and billing solutions for independent pharmacies. It also functions as a distributor, supplying pharmaceutical goods to standalone drugstores and other healthcare providers. Established in 2008, ScripsAmerica is based in Clifton, New Jersey. The company initially filed for Chapter 11 bankruptcy protection on September 7, 2016, before its reorganization case was subsequently changed to Chapter 7 liquidation on February 8, 2017.
—
Daily adjusted close
ScripsAmerica, Inc. specializes in crafting and selling non-sterile creams for topical and transdermal pain management. Beyond its product offerings, the company provides medication dispensing support to individual doctors and supplies administrative and billing solutions for independent pharmacies. It also functions as a distributor, supplying pharmaceutical goods to standalone drugstores and other healthcare providers. Established in 2008, ScripsAmerica is based in Clifton, New Jersey. The company initially filed for Chapter 11 bankruptcy protection on September 7, 2016, before its reorganization case was subsequently changed to Chapter 7 liquidation on February 8, 2017.